93 related articles for article (PubMed ID: 9410067)
1. [Meropenem: pharmacologic advantages of clinical interest].
Domínguez-Gil Hurlé A
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():32-7. PubMed ID: 9410067
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of meropenem in subjects with renal insufficiency.
Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
[TBL] [Abstract][Full Text] [Related]
4. Meropenem clinical pharmacokinetics.
Mouton JW; van den Anker JN
Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
[TBL] [Abstract][Full Text] [Related]
8. Meropenem: a new carbapenem antimicrobial.
Pryka RD; Haig GM
Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
[TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
Conte JE; Golden JA; Kelley MG; Zurlinden E
Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
Abo El Sooud K
J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of meropenem.
Drusano GL; Hutchison M
Scand J Infect Dis Suppl; 1995; 96():11-6. PubMed ID: 7652497
[TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
Bidgood T; Papich MG
Am J Vet Res; 2002 Dec; 63(12):1622-8. PubMed ID: 12492274
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S; Punyo J
Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium].
Fujii R; Meguro H; Arimasu O; Yoshioka H; Fujita K; Maruyama S; Inyaku F; Nagamatsu I; Wagatsuma Y; Takase A
Jpn J Antibiot; 1986 Jul; 39(7):1912-37. PubMed ID: 3464785
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of imipenem in healthy volunteers.
Norrby SR; Björnegård B; Ferber F; Jones KH
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():109-24. PubMed ID: 6583194
[TBL] [Abstract][Full Text] [Related]
19. Laboratory data which differentiate meropenem and imipenem.
Edwards JR; Turner PJ
Scand J Infect Dis Suppl; 1995; 96():5-10. PubMed ID: 7652504
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
